Escalon® Medical Corp. to Introduce Sonomed Escalon VuPad™ at Annual Meeting of the American Academy of Ophthalmology

 Escalon® Medical Corp. to Introduce Sonomed Escalon VuPad™ at Annual Meeting
                   of the American Academy of Ophthalmology

PR Newswire

ARDMORE, Pa., Nov. 14, 2013

ARDMORE, Pa., Nov. 14, 2013 /PRNewswire/ -- Escalon Medical Corp. (Nasdaq:
ESMC) today announced its plans to introduce a new tablet-based ultrasound
imaging system, the Sonomed Escalon VuPad™, at the upcoming 117th Annual
Meeting of the American Academy of Ophthalmology (AAO) November 16-19^th at
the Ernest N. Morial Convention Center in New Orleans. The product will be
featured at the Sonomed Escalon booth 1316.

The VuPad™ offers A-scan, B-scan, and/or UBM modalities in a sleek,
tablet-like package. Key features include portable ergonomic design, elegant
user interface, wireless interconnectivity to EMR's, image management systems,
and printers, multi-touch ultra high resolution touch screen with pinch zoom
functionality, and most notably, outstanding image quality and measurement

Chief Executive Officer, Richard J. DePiano Jr. commented, "We are excited to
introduce the VuPad™, the latest in portable ultrasound technology. Its
upcoming launch, along with the VuMAX® HD introduced earlier this calendar
year, demonstrates the Company's continued focus on developing and delivering
new best-in-class ophthalmic ultrasound solutions."

The Company anticipates shipments of VuPad™ systems as early as the end of the
calendar year following clearance from FDA and other regulatory bodies.

For additional information about the AAO visit

About Escalon Medical
Founded in 1987, Escalon Medical Corp. (NASDAQ: ESMC)  specializes in the
development, marketing and distribution of ophthalmic diagnostic imaging and
surgical products branded under the Sonomed Escalon name.Products include a
variety of ophthalmic ultrasound, digital imaging and photography, and image
management systems as well as surgical products including intraocular gases,
fiber optic light guides and sources, and other surgical vitreoretinal
instruments. The Company seeks to grow its ophthalmic business by further
developing and diversifying its product offering through internal development
programs, strategic partnerships, and the acquisition of technology so as to
best leverage the Company's distribution capabilities. The Company has
headquarters in Ardmore, Pennsylvania and research and development,
manufacturing and distribution operations in Lake Success, New York, New
Berlin, Wisconsin and Stoneham, Massachusetts. For additional information
visit and

Forward Looking Statements
This press release contains statements that are considered forward-looking
under the Private Securities Litigation Reform Act of 1995, including
statements about the Company's future prospects. These statements are based on
the Company's current expectations and are subject to a number of
uncertainties and risks, and actual results may differ materially. The
uncertainties and risks include whether the Company is able to: implement its
growth and marketing strategies, improve upon the operations of the Company
including the ability to make acquisitions and the integration of any
acquisitions it may undertake, if any, of which there can be no assurance;
grow our remaining ophthalmic business unit; improve our financial position;
implement cost reductions; generate cash; and identify, finance and enter into
business relationships and acquisitions. Other factors include uncertainties
and risks related to: new product development, commercialization,
manufacturing and market acceptance of new products; marketing acceptance of
existing products in new markets; research and development activities,
including failure to demonstrate clinical efficacy; delays by regulatory
authorities, scientific and technical advances by the Company or third
parties; introduction of competitive products; ability to reduce staffing and
other costs and retain benefit of prior reductions; third party reimbursement
and physician training, and general economic conditions. Further information
about these and other relevant risks and uncertainties may be found in the
Company's report on Form 10- K for year ended June 30, 2013, and its other
filings with the Securities and Exchange Commission, all of which are
available from the Securities and Exchange Commission as well as other

SOURCE Escalon Medical Corp.

Contact: Richard J. DePiano, Jr., President and CEO, 610-688-6830; Alison
Ziegler, Cameron Associates, 212-554-5469
Press spacebar to pause and continue. Press esc to stop.